Selective Cytopheresis Therapy in Systemic Inflammatory Response Syndrome

全身炎症反应综合征的选择性细胞分离疗法

• 批准号: 7392968
• 负责人: DEBORAH Ann BUFFINGTON
• 金额: $ 25.14万
• 依托单位: INNOVATIVE BIOTHERAPIES, INC.
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-03-01 至 2010-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7392968
• 关键词: Acute; Adult Respiratory Distress Syndrome; Animals; Antibiotics; Area; Bacteria; Blood Pressure; Bronchoalveolar Lavage; Cardiovascular system; Cessation of life; Clinical; Data; Devices; Disease; Disease Progression; Drug Formulations; Family suidae; Functional disorder; Hour; Inflammation; Inflammatory; Inflammatory Response; Innovative Therapy; Intensive Care Units; Investigation; Lead; Leukocytes; Marketing; Membrane; Modeling; Names; Newborn Respiratory Distress Syndrome; Numbers; Pathogenesis; Patients; Phase; Placebos; Pneumonia; Pre-Clinical Model; Process; Proteins; Pump; Rate; Renal tubule structure; Reperfusion Injury; Research Proposals; Sepsis; Sepsis Syndrome; Septic Shock; Site; Small Business Funding Mechanisms; Small Business Innovation Research Grant; Surface; System; Testing; Therapeutic; Time; Tissues; cytokine; improved; mortality; neutrophil; novel therapeutics; research study

DESCRIPTION (provided by applicant): An extracorporeal device, named selective cytopheretic device (SCD), has been fabricated that sequesters activated leukocytes and inhibits their release of inflammatory proteins and cytokines. Leukocytes are major contributors to the pathogenesis and progression of many clinical inflammatory disorders, including the systemic inflammatory response syndrome (SIRS), sepsis and acute respiratory distress syndrome (ARDS). A large number of therapeutic approaches are under investigation to limit the activation and tissue accumulation of leukocytes at sites of inflammation in order to minimize tissue destruction and disease progression. This research proposal will evaluate this SCD on a well-developed porcine model of septic shock, SIRS and early ARDS. Various cardiovascular parameters, systemic cytokine levels, and pulmonary inflammation with bronchoalveolar lavage (BAL) parameters and time to death will be compared between treatment and sham treatment groups. The effects of membrane surface area and efficacy of a simplified circuit system on the ongoing multiorgan dysfunction and inflammatory processes will also be assessed. This proposal may suggest a manner of altering the systemic inflammatory response and may lead to a new therapeutic approach to sepsis, SIRS and ARDS.

描述（由申请人提供）：制造了一种名为选择性细胞分离装置（SCD）的体外装置，可隔离活化的白细胞并抑制其释放炎性蛋白和细胞因子。白细胞是许多临床炎症性疾病的发病机制和进展的主要贡献者，包括全身炎症反应综合征（SIRS）、脓毒症和急性呼吸窘迫综合征（ARDS）。大量的治疗方法正在研究中，以限制炎症部位白细胞的激活和组织积聚，从而最大限度地减少组织破坏和疾病进展。这项研究计划将在一个发育良好的感染性休克、SIRS和早期ARDS猪模型上评价这种SCD。将比较治疗组和假治疗组之间的各种心血管参数、全身细胞因子水平和肺部炎症与支气管肺泡灌洗（BAL）参数和至死亡时间。还将评估膜表面积和简化回路系统对持续多器官功能障碍和炎症过程的有效性的影响。这一建议可能提示改变全身炎症反应的方式，并可能导致脓毒症，SIRS和ARDS的新的治疗方法。